CSIR-CDRI and Dr Reddy’s Laboratories Partner to Develop High-value Generics in the API Value Chain

CSIR-Central Drug Research Institute (CSIR-CDRI), Lucknow, and Dr Reddy's Laboratories Ltd, Hyderabad, have entered into an agreement on 22 November 2023 for the development of high-value generics in Active Pharmaceutical Ingredients (APIs) value chain (starting materials & Intermediates). The collaboration aims to develop cost-effective and industrially viable processes for selected generic drugs. A group of expert synthetic chemists from CSIR-CDRI and Dr Reddy’s will work jointly to deliver the project goals. Upon successful execution, the collaboration would be expanded to other drug discovery and development areas, focusing on affordable healthcare.

Dr Radha Rangarajan, Director, CSIR-CDRI, said, “We are excited to work with Dr Reddy’s for the development of APIs. Our shared goal of delivering high-quality drug products while ensuring affordability and access makes this collaboration particularly meaningful.”

Deepak Sapra, Chief Executive Officer, API and Services, Dr Reddy’s, said, “We are delighted to collaborate with CSIR-CDRI and hope to foster deep industry-academia linkages. Such engagements allow for the best of public-private infrastructure, talent, and knowledge to be harnessed for global health. The collaboration also aligns with our patient goals of serving 1.5 billion patients by 2030 globally and launching innovative products with increased accessibility and affordability.”